Denver, Colo.- This morning’s market narrative is about transition, as companies resetting capital structures, extending runways, locking in long-term partnerships, and positioning themselves for the next leg of growth as investors sort conviction from volatility.
FAT Brands (NASDAQ:FAT) is attempting to stabilize after filing voluntary Chapter 11 petitions earlier this week, a move management says is designed to “strengthen our capital structure” and support long-term growth. Importantly for customers and franchisees, FAT’s 18-brand portfolio, including Fatburger, Johnny Rockets, and Round Table Pizza, is expected to continue operating as usual during the process. With more than 2,200 locations worldwide and roughly 45,000 corporate and franchise employees, the restructuring is being framed as a financial reset rather than an operational retreat. Trading is expected to continue with a “Q” suffix as the process unfolds, and early trading action suggests some investors are positioning for a potential reversal if confidence builds around deleveraging progress.
Twin Hospitality Group (NASDAQ;TWNP) is drawing trader attention after rebounding from a new 52-week low of $0.25, following its announcement earlier this week that it filed voluntary Chapter 11 petitions aimed at strengthening its capital structure. The parent company of Twin Peaks Restaurant and Smokey Bones confirmed Monday that the restructuring process is designed to deleverage the balance sheet, maximize stakeholder value, and support the continued growth of its brands. Management emphasized that all restaurants are expected to remain open and operating as usual throughout the Chapter 11 process, with no disruption to customer experience or franchise operations. Trading in TWNP shares is expected to continue on Nasdaq with a “Q” suffix during the proceedings. Chief Executive Officer Andy Wiederhorn highlighted the long-term positioning of the Twin Peaks brand, noting its profitability and global expansion potential, while framing the filing as a strategic step to create financial flexibility rather than an operational retreat. The company plans to engage stakeholders on a value-maximizing plan while maintaining support for franchise partners and its workforce.
Expansion, rather than retrenchment, is the story at VivoSim Labs (NASDAQ:VIVS), which announced new distribution agreements in Korea and China to broaden access to its NAMKind human-based toxicology services. By appointing JCBio in Korea and Tekon Biotech in China, VivoSim is extending its reach into Asia-Pacific at a time when demand for New Approach Methodologies (NAMs) is accelerating globally. Management highlighted the appeal of its “molecules in, data out” model, designed to deliver human-relevant liver and GI toxicity data with a targeted 30-day turnaround, an increasingly valuable proposition as regulators and drug developers seek earlier, more predictive safety signals.
On the innovation front, Kraig Biocraft Laboratories (OTCQB:KBLB) continues to attract attention at the intersection of materials science and biotechnology. The company is advancing genetically engineered spider silk produced in silkworms using CRISPR-enabled and adjacent gene-editing tools, an effort aimed at commercializing high-performance fibers long viewed as impractical to scale. The work highlights how gene-editing technologies are increasingly being applied beyond medicine, into advanced textiles, protective equipment, and composites.
Cybersecurity and identity assurance remain in focus with authID (NASDAQ:AUID), which announced it was selected, alongside partner MajorKey, by a global personal care retailer generating more than $6 billion in annual sales. The deployment will support biometric identity onboarding and privileged access protection for employees and third-party contractors across multiple countries. Management cited rising risks from AI-generated impostors and hiring fraud, positioning authID’s privacy-preserving biometric approach as a solution for enterprises facing growing insider threat vectors without compromising compliance or user experience.
In biotech financing, ProMIS Neurosciences (NASDAQ:PMN) announced a sizeable private placement of up to $175 million, extending its cash runway into 2028. The PIPE financing, led by Janus Henderson and Ally Bridge Group, is expected to fund completion of ProMIS’ Phase 1b Alzheimer’s disease study for PMN310, with blinded six-month top-line data anticipated mid-2026. Management described the raise as “transformational,” enabling both clinical execution and advancement of a subcutaneous formulation while keeping multiple neurodegenerative programs on track.
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.